Trials / Completed
CompletedNCT03073200
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 201 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SC |
| DRUG | Placebo | Administered SC |
| DRUG | Etanercept | Administered SC |
Timeline
- Start date
- 2017-03-28
- Primary completion
- 2019-02-07
- Completion
- 2021-03-23
- First posted
- 2017-03-08
- Last updated
- 2021-09-27
- Results posted
- 2020-03-17
Locations
69 sites across 13 countries: United States, Argentina, Canada, Czechia, France, Germany, Hungary, Mexico, Netherlands, Poland, Puerto Rico, Russia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03073200. Inclusion in this directory is not an endorsement.